钠-葡萄糖共转运蛋白2抑制剂治疗2型糖尿病合并非酒精性脂肪肝的研究进展

Research progress of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes mellitus with non-alcoholic fatty liver

随着全球范围内肥胖和2型糖尿病(type 2 diabetes mellitus,T2DM)发病率的急剧增长,约70%的肥胖糖尿病患者同时合并有非酒精性脂肪肝(non-alcoholic fatty liver disease,NAFLD),甚至多达30%~40%的患者合并有非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NA SH)。目前T2DM合并NAFLD已成为全球关注的健康问题之一。尽管如此,近年来大量相关研究表明钠-葡萄糖共转运蛋白2(sodium-glucose co-transporter 2,SGLT2)抑制剂显著降糖的同时,肝相关不良事件的发生明显减少,为NAFLD的治疗提供了新思路。

With the incidence of obesity and type 2 diabetes mellitus（T2DM） increasing dramatically worldwide, about 70% of obese diabetics combined with non-alcoholic fatty liver disease（NAFLD） and even as many as 30%–40% combined with non-alcoholic steatohepatitis（NASH）. At present, T2DM with NAFLD has become one of the global health concerns. Even so, in recent years, a great deal of researches on sodium-glucose co-transporter 2（SGLT2） inhibitors have shown that they have remarkable effect of lowering blood sugar, also, the incidence of adverse events related to liver has significantly reduced, thus providing new ideas for the treatment of NAFLD.